Cellshift manufactures compact, GMP-ready bioreactors tailored for autologous cell therapies, addressing supply chain bottlenecks in Australian hospitals. The Adelaide-based team includes veterans from the SA Pathology and draws on expertise from the University of Adelaide's bioengineering group. The first system is slated for installation at a major teaching hospital in 2025.